This perspective piece argues for a transition from a standardized manufacturing model to a precision product framework in the development of mesenchymal stem/stromal cell (MSC) therapies. The author highlights a critical paradox where regulatory standards prioritize high cell viability, yet therapeutic success in inflammatory diseases often depends on host-mediated clearance of apoptotic cells, a...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动